

Copper-Mediated Amidation of Heterocyclic and Aromatic C-H Bonds

*Qiu Wang and Stuart L. Schreiber**

*Howard Hughes Medical Institute, Broad Institute, Cambridge, MA 02142;
Department of Chemistry and Chemical Biology, Harvard University, Cambridge,
MA 02138*

Supporting Information

Content:


Material and method	S1
Supplementary tables for condition optimizations	S2
General experimental procedure	S3
Characterization data of new compounds	S3-S8
^1H and ^{13}C NMR spectra	S9-S38

Material and Method.

Except as otherwise noted, commercial reagents and solvents were used as received without further purification. Proton nuclear magnetic resonance (^1H NMR) spectra and carbon nuclear magnetic resonance (^{13}C NMR) spectra were recorded with Varian Unity/Inova 500 (500 MHz/125 MHz) or Bruker Biospin 300 (300 MHz/75 MHz) spectrometer. Fluoride nuclear magnetic resonance (^{19}F NMR) spectra were recorded with Bruker Biospin 300 (282 MHz). Chemical shifts for protons are reported in parts per million (δ scale) and are referenced to residual protium in the NMR solvents (CHCl_3 : δ 7.27, D_2HCOD : δ 3.31). Chemical shifts for carbon are reported in parts per million (δ scale) and are referenced to the carbon resonances of the solvent (CDCl_3 : δ 77.0, CD_3OD : δ 49.1, $(\text{CD}_3)_2\text{SO}$: δ 40.5). Data are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constant in Hz, and integration. Infrared spectra were recorded using a Perkin-Elmer FT-IR spectrometer (thin film or neat, as indicated). High-resolution mass spectra were obtained through the Harvard University mass spectrometry facilities. Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Flash chromatography was performed on a CombiFlash companion system (Teledyne ISCO, Inc.) with pre-packed FLASH silica gel columns (Biotage, Inc.).

Supplementary tables.

Table S1. Selected screening results for coupling reaction of **1** with amide nucleophile **2a**.



Entry	Reaction condition (equiv of the reagents)	Solvent	Time	Yield ^b of 3a/4/1 (%)
1	1 (1.0), 2a (2.0), Cu(OAc) ₂ (0.2), Na ₂ CO ₃ (2.0)	Toluene	24 h	10/-/81
2	1 (1.0), 2a (2.0), Cu(OAc) ₂ (0.2), Na ₂ CO ₃ (2.0), Pyr. (5.0)	Toluene	24 h	58/30/-
3	1 (1.0), 2a (5.0), Cu(OAc) ₂ (0.2), Na ₂ CO ₃ (2.0), Pyr. (5.0)	Toluene	24 h	16/-/79
4	1 (1.0), 2a (5.0), Cu(OAc) ₂ (0.2), Na ₂ CO ₃ (2.0), pyr. (10.0)	Toluene	36 h ^c	88 ^d /6/-
5	1 (1.0), 2a (5.0), Cu(OAc)2 (0.2), Na2CO3 (2.0), pyr. (20.0)	Toluene	12 h^c	82^d/10/-
6	1 (1.0), 2a (5.0), Cu(OAc) ₂ (1.0), Na ₂ CO ₃ (2.0), pyr. (20.0)	Toluene	4 h ^c	65 ^d /23/-
7	1 (1.0), 2a (5.0), CuCl ₂ (0.2), Na ₂ CO ₃ (2.0), pyr. (20.0)	Toluene	16 h	74/-/12
8	1 (1.0), 2a (5.0), CuBr ₂ (0.2), Na ₂ CO ₃ (2.0), pyr. (20.0)	Toluene	16 h	9/-/56
9	1 (1.0), 2a (5.0), Cu(OTf) ₂ (0.2), Na ₂ CO ₃ (2.0), pyr. (20.0)	Toluene	16 h	28/-/52
10	1 (1.0), 2a (5.0), Cu(OCOCF ₃) ₂ (0.2), Na ₂ CO ₃ (2.0), pyr. (20.0)	Toluene	16 h	13/-/81
11	1 (1.0), 2a (5.0), Cu(OAc) ₂ (0.2), Na ₂ CO ₃ (2.0), lutidine (20.0)	Toluene	16 h	14/-/81
12	1 (1.0), 2a (5.0), Cu(OAc) ₂ (0.2), Na ₂ CO ₃ (2.0), TMEDA (20.0)	Toluene	16 h	14/-/77

^aStandard condition: **1** (0.3 mmol), toluene (10 mL), O₂ (balloon), 140 °C. ^bYields of **3a**, **4** and **1** determined by ¹H-NMR.

^cRequired reaction time for completely consuming **1**. ^dIsolated yield of **3a**. ^eAbbreviations: pyr. = pyridine, TMEDA = *N,N'*-tetramethylethylenediamine.


General procedure for the copper-mediated amidation reaction.

To a dry flask, were added the heterocycle, the amide nucleophile, the base and Cu(OAc)₂ respectively. An atmosphere of oxygen was introduced by briefly evacuating the flask, then flushing with pure oxygen (1 atm). Toluene and pyridine were added to the flask. The resulting green mixture was allowed to stir at room temperature for 30 mins and then heat at 120-140 °C for 12-30 h. After the limiting starting material was completely consumed, the reaction mixture was cooled down to room temperature and diluted with EtOAc. The mixture was washed with aqueous ammonium, brine, and dried over Na₂SO₄. The dried solution was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was further purified by silica gel chromatography.


Procedure for the preparation of bezimidazole precursors 9 and 10.

To the colorless solution of Tosyl-Cl (106 mg, 0.56 mmol) in CH₂Cl₂ (5 ml), was added 2-(1H-benzo[d]imidazol-1-yl)ethanamine hydrochloride or 3-(1H-benzo[d]imidazol-1-yl)propan-1-amine hydrochloride (0.51 mmol) slowly at room temperature. The solution was stirred for 2 h and then diluted with water. The aqueous layer was separated and extracted with EtOAc. The combined organic layers were washed with brine and dried over Na₂SO₄. The dried solution was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was further purified by silica gel chromatography.


Characterizations of new compounds.




1-(1-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one (3a). Yield: 82%. R_f = 0.25 (100% ethyl acetate); ¹H NMR (500 MHz, CDCl₃) δ 7.71-7.64 (m, 1H), 7.35-7.30 (m, 1H), 7.30-7.21 (m, 2H), 4.08 (t, J = 7.0 Hz, 2H), 3.69 (s, 3H), 2.61 (t, J = 8.0 Hz, 2H), 2.27 (tt, J = 8.0, 7.0 Hz, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 175.1, 146.2, 140.7, 134.9, 122.4, 122.2, 118.9, 109.3, 49.2, 31.3, 31.2, 19.1; IR (neat): 2984, 294, 1735, 1516, 1373, 1235, 1043 cm⁻¹. HRMS-ESI (m/z) -ESI m/z calcd. for C₁₂H₁₃N₃ONa [M+Na] 238.0951; Found: 238.0948.




1-(1-methyl-1H-benzo[d]imidazol-2-yl)piperidin-2-one (3b). Yield: 55%. R_f = 0.20 (100% ethyl acetate); ¹H NMR (500 MHz, CDCl₃) δ 7.72 (d, J = 7.3 Hz, 1H), 7.35 (d, J = 7.3 Hz, 1H), 7.33-7.25 (m, 2H), 3.92 (t, J = 5.5 Hz, 2H), 3.62 (s, 3H), 2.64 (t, J = 6.3 Hz, 2H), 2.14-1.94 (m, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 171.0, 149.3, 140.9, 134.7, 122.7, 122.2, 119.5, 109.5, 50.7, 32.9, 30.3, 23.2, 21.2; IR (neat): 3056, 2948, 1668, 1509, 1480, 1442, 1396, 1329, 1285, 1160, 908, 740 cm⁻¹, HRMS-ESI (m/z) calcd. for C₁₃H₁₅N₃ONa [M+Na] 252.1107; Found: 252.1112.




1-(1-methyl-1H-benzo[d]imidazol-2-yl)azocan-2-one (3c). Yield: 55%. R_f = 0.30 (100% ethyl acetate); ¹H NMR (500 MHz, CDCl₃) δ 7.74 (d, J = 7.6 Hz, 1H), 7.37 – 7.25 (m, 3H), 4.01 (t, J = 6.0 Hz, 2H), 3.64 (s, 3H), 2.76 (t, J = 5.0 Hz, 2H), 2.06-1.89 (m, 4H), 1.85-1.70 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 175.9, 149.1, 140.8, 134.7, 122.6, 122.0, 119.6, 109.4, 50.2, 34.1, 30.5, 30.3, 28.5, 26.1, 24.7; IR (neat): 2926, 1664, 1508, 1475, 1439, 1392, 1329, 12383, 1129, 912, 727, 561 cm⁻¹. HRMS-ESI (m/z) calcd. for C₁₅H₂₀N₃O [M+1]: 258.1601; Found: 258.1604.




1-methyl-3-(1-methyl-1H-benzo[d]imidazol-2-yl)imidazolidin-2-one (3d). Yield: 45%. R_f = 0.20 (100% ethyl acetate); ¹H NMR (500 MHz, CDCl₃) δ 7.68 (d, J = 7.0 Hz, 1H), 7.35 (d, J = 7.0 Hz, 1H), 7.32-7.27 (m, 2H), 4.16 (t, J = 7.6 Hz, 2H), 3.81 (s, 3H), 3.63 (t, J = 7.6 Hz, 2H), 2.97 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.7, 148.0, 140.8, 135.4, 122.0, 121.9, 118.5, 109.2, 44.9, 43.5, 31.5, 31.1; IR (neat): 3051, 1717, 1523, 1482, 1429, 1398, 1278, 1264, 1230, 726 cm⁻¹. HRMS-ESI (m/z) calcd. for C₁₂H₁₄N₄ONa [M+Na]: 253.1060, Found: 253.1066.




3-(1-methyl-1*H*-benzo[*d*]imidazol-2-yl)oxazolidin-2-one (3e). Yield: 72%. $R_f = 0.20$ (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 7.69 (d, $J = 7.0$ Hz, 1H), 7.36–7.27 (m, 3H), 4.61 (t, $J = 7.5$ Hz, 2H), 4.34 (t, $J = 7.5$ Hz, 2H), 3.78 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 155.4, 145.2, 140.4, 135.1, 122.7, 122.5, 118.9, 109.4, 63.4, 46.3, 31.2; IR (neat): 2911, 1763, 1524, 1483, 1449, 1401, 1228, 1209, 1133, 1037, 746 cm^{-1} . HRMS–ESI (m/z) calcd. for $\text{C}_{11}\text{H}_{12}\text{N}_3\text{O}_2$ [M+1]: 218.0924; Found: 218.0926.




4-benzyl-3-(1-methyl-1*H*-benzimidazol-2-yl)-1,3-oxazolidin-2-one (3f). Yield: 64%. $R_f = 0.30$ (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 7.90–7.62 (m, 1H), 7.41–7.22 (m, 6H), 7.08 (d, $J = 7.2$ Hz, 2H), 5.18 (qd, $J = 8.5, 4.0$ Hz, 1H), 4.55 (t, $J = 8.5$ Hz, 1H), 4.34 (t, $J = 8.5$ Hz, 1H), 3.73 (s, 3H), 3.23 (dd, $J = 13.8, 4.0$ Hz, 1H), 2.95 (dd, $J = 13.8, 8.5$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 155.4, 144.4, 140.9, 135.0, 134.5, 129.2, 128.8, 127.3, 122.8, 122.5, 119.3, 109.5, 68.1, 58.0, 37.8, 30.8; IR (neat): 1762, 1709, 1399, 1360, 1220, 729, 702 cm^{-1} . HRMS–ESI (m/z) calcd. for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2\text{Na}$ [M+Na]: 330.1213, Found: 330.1209.




N,4-dimethyl-N-(1-methyl-1*H*-benzimidazol-2-yl)benzenesulfonamide (3g). Yield: 50%. $R_f = 0.30$ (30% ethyl acetate-hexanes); ^1H NMR (300 MHz, CDCl_3) δ 7.67 (d, $J = 7.6$ Hz, 1H), 7.60 (d, $J = 8.3$ Hz, 2H), 7.43 – 7.38 (m, 1H), 7.36 (dd, $J = 6.9, 1.2$ Hz, 1H), 7.34 – 7.25 (m, 3H), 3.91 (s, 3H), 3.20 (s, 3H), 2.44 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 147.7, 144.8, 140.3, 134.7, 132.1, 129.7, 128.8, 123.4, 122.6, 119.6, 110.0, 38.1, 30.8, 21.6; IR (neat): 3055, 1394, 1352, 1160, 779, 700 cm^{-1} . HRMS–ESI (m/z) calcd. for $\text{C}_{16}\text{H}_{17}\text{N}_3\text{O}_2\text{SNa}$ [M+Na]: 338.0934, Found: 338.0928.



N-(1-methyl-1*H*-benzimidazol-2-yl)benzamide (3h). Yield: 85%. $R_f = 0.30$ (30% ethyl acetate-hexanes); ^1H NMR (300 MHz, CDCl_3) δ 8.36 (d, $J = 6.9$ Hz, 2H), 7.60 – 7.41 (m, 3H), 7.40 – 7.21 (m, 4H), 3.82 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 176.3, 153.9, 137.9, 131.2, 130.2, 129.2, 128.3, 127.9, 123.0 (2), 111.2, 108.9, 28.2. HRMS cald for $\text{C}_{15}\text{H}_{14}\text{N}_3\text{O}$ [M+H]: 252.1131, Found: 252.1136.




N-(1-methyl-1*H*-benzo[*d*]imidazol-2-yl)-2-(trifluoromethyl)benzamide (3i). Yield: 91%. $R_f = 0.30$ (20% ethyl acetate-hexanes); ^1H NMR (500 MHz, D_2O) δ 12.27 (brs, 1H), 7.93 (d, $J = 7.6$ Hz, 1H), 7.73 (d, $J = 7.6$ Hz, 1H), 7.58 (t, $J = 7.6$ Hz, 1H), 7.49 (t, $J = 7.6$ Hz, 1H), 7.32–7.22 (m, 4H), 3.69 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 177.9, 153.5, 139.8, 131.4, 130.0, 129.9, 129.0, 128.0, 127.8 (q, $J = 31.5$ Hz), 126.4 (q, $J = 5.5$ Hz), 124.2 (q, $J = 274.5$ Hz), 123.4, 123.3, 111.3, 109.2, 28.3; IR (neat): 3274, 1736, 1571, 1484, 1383, 1365, 1315, 1135 cm^{-1} . HRMS–ESI (m/z) calcd. for $\text{C}_{16}\text{H}_{12}\text{F}_3\text{N}_3\text{ONa}$ [M+Na]: 342.0825; Found: 342.0825.




2-methoxy-N-(1-methyl-1*H*-benzo[*d*]imidazol-2-yl)benzamide (3j). Yield: 72%. $R_f = 0.30$ (20% ethyl acetate-hexanes); ^1H NMR (300 MHz, CDCl_3) δ 12.45 (brs, 0.5H), 10.15 (brs, 0.5H), 8.18 (d, $J = 6.6$ Hz, 1H), 7.50 (t, $J = 7.2$ Hz, 2H), 7.36–7.18 (m, 3H), 7.17–6.86 (m, 2H), 4.02 (s, 3H), 3.75 (s, 3H). ^{13}C NMR (125 MHz, CD_3OD) δ


1169.4, 159.5, 147.4, 136.8, 135.3, 134.2, 132.6, 124.8, 124.6, 123.4, 122.2, 117.2, 113.3, 111.3, 56.9, 30.4; IR (neat): 3298, 1602, 1571, 1483, 1375, 1244, 747 cm^{-1} . HRMS-ESI (m/z) calcd. for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}_2\text{Na}$ [M+Na]: 304.1057; Found: 304.1054.




N-(1-methyl-1H-benzo[d]imidazol-2-yl)-4-(trifluoromethyl)benzamide (3k). Yield: 70%. $R_f = 0.30$ (20% ethyl acetate-hexanes); ^1H NMR (300 MHz, CDCl_3) δ 12.28 (s, 1H), 8.46 (d, $J = 8.1$ Hz, 2H), 7.71 (d, $J = 8.1$ Hz, 2H), 7.41 – 7.22 (m, 4H), 3.81 (s, 3H); ^{13}C NMR (125 MHz, DMSO) δ 171.8, 152.3, 141.8, 130.6 (q, $J = 32.0$ Hz), 129.8, 129.1, 128.5, 124.6 (q, $J = 3.0$ Hz), 124.0 (q, $J = 272.5$ Hz), 122.5 (2C), 111.8, 109.3, 28.1; IR (neat): 3278, 1578, 1560, 1321, 1104, 1064, 746 cm^{-1} . HRMS-ESI (m/z) calcd. for $\text{C}_{16}\text{H}_{13}\text{F}_3\text{N}_3\text{O}$ [M+1] 320.1005; Found: 320.1045.




4-methoxy-N-(1-methyl-1H-benzimidazol-2-yl)benzamide (3l). Yield: 67%. $R_f = 0.30$ (20% ethyl acetate-hexanes); ^1H NMR (300 MHz, CDCl_3) δ 8.33 (d, $J = 8.6$ Hz, 2H), 7.44 – 7.15 (m, 4H), 6.96 (d, $J = 8.6$ Hz, 2H), 3.89 (s, 3H), 3.79 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 176.3, 162.3, 154.2, 131.1, 130.8, 130.3, 128.3, 123.0, 114.1, 113.2, 111.0, 108.9, 55.3, 28.2; IR (neat): 1572, 1321, 1251, 689, 668 cm^{-1} . HRMS-ESI (m/z) calcd. for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}_2\text{Na}$ [M+Na]: 304.1057; Found: 304.1054.




N-(1-methyl-1H-benzo[d]imidazol-2-yl)pivalamide (3m). Yield: 58%. $R_f = 0.30$ (20% ethyl acetate-hexanes); ^1H NMR (500 MHz, CDCl_3) δ 12.16 (brs, 1H), 7.25-7.17 (m, 4H), 3.63 (s, 3H), 1.29 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ 173.6, 154.0, 130.7, 129.1, 122.8, 122.6, 111.2, 108.8, 41.1, 28.2, 28.1; IR (neat): 3253, 2952, 1593, 1548, 1477, 1391, 739 cm^{-1} . HRMS-ESI (m/z) calcd. for $\text{C}_{13}\text{H}_{18}\text{N}_3\text{O}$ [M+H]: 232.1444; Found: 232.1455.




2,2,2-trifluoro-N-(1-methyl-1H-benzo[d]imidazol-2-yl)acetamide (3n). Yield: 68%. $R_f = 0.30$ (20% ethyl acetate-hexanes); ^1H NMR (500 MHz, CDCl_3) δ 11.97 (brs, 1H), 7.48 (d, $J = 6.6$ Hz, 2H), 7.41-7.32 (m, 3H), 3.76 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 166.8 – 165.8 (m), 153.1, 129.8, 127.8, 124.3, 124.2, 117.2 (q, $J = 286.0$ Hz), 112.1, 109.8, 28.7; IR (neat): 3230, 2922, 1549, 1481, 1124, 741 cm^{-1} . HRMS-ESI (m/z) calcd. for $\text{C}_{10}\text{H}_9\text{F}_3\text{N}_3\text{O}$ [M+1]: 244.0692; Found: 244.0696.




4-bromo-N-(1-methyl-1H-benzo[d]imidazol-2-yl)benzenesulfonamide (3o). Yield: 97%. $R_f = 0.30$ (20% ethyl acetate-hexanes); ^1H NMR (500 MHz, CDCl_3) δ 10.62 (brs, 1H), 7.87 (d, $J = 8.6$ Hz, 2H), 7.56 (d, $J = 8.6$ Hz, 2H), 7.35-7.31 (m, 1H), 7.24-7.18 (m, 2H), 7.13 (d, $J = 7.0$ Hz, 1H), 3.52 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 149.7, 142.7, 131.9, 130.3, 128.2, 127.6, 126.4, 123.5, 123.2, 111.1, 108.9, 28.4; IR (neat): 3357, 3091, 1578, 1483, 1271, 1129, 1084, 1001, 821, 735, 637 cm^{-1} . HRMS-ESI (m/z) calcd. for $\text{C}_{14}\text{H}_{13}\text{BrN}_3\text{O}_2\text{S}$ [M+1]: 365.9906; Found: 365.9915.




4-methyl-N-(1-methyl-1*H*-benzo[*d*]imidazol-2-yl)benzenesulfonamide (3p). Yield: 86%. R_f = 0.30 (20% ethyl acetate-hexanes); ¹H NMR (300 MHz, CDCl₃) δ 10.69 (brs, 1H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.36-7.29 (m, 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.21-7.15 (m, 2H), 7.13-7.07 (m, 1H), 3.50 (s, 3H), 2.37 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 149.8, 142.2, 140.8, 130.3, 129.3, 128.3, 126.0, 123.2, 122.9, 111.1, 108.7, 28.3, 21.4; IR (neat): 3312, 2925, 1711, 1585, 1275, 1132, 1084, 829, 746, 673, 533 cm⁻¹. HRMS-ESI (*m/z*) calcd. for C₁₅H₁₆N₃O₂S [M+1]: 302.0956; Found: 302.0964.




1-(benzo[*d*]thiazol-2-yl)pyrrolidin-2-one (5a). Yield: 45%. R_f = 0.50 (50% ethyl acetate-hexanes); ¹H NMR (300 MHz, CDCl₃) δ 7.79-7.86 (t, *J* = 7.7 Hz, 2H), 7.43 (td, *J* = 7.7, 1.3 Hz, 1H), 7.31 (td, *J* = 7.7, 1.3 Hz, 1H), 4.27 (t, *J* = 7.2 Hz, 2H), 2.74 (t, *J* = 8.0 Hz, 2H), 2.29 (tt, *J* = 8.0, 7.2 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 174.2, 157.1, 148.7, 132.4, 126.0, 123.9, 121.3 (2C), 48.2, 31.9, 18.1; IR (neat): 3034, 1709, 1510, 1360, 1221, 917, 730, 529 cm⁻¹. HRMS-ESI (*m/z*) calcd. for C₁₁H₁₀N₂OSNa [M+Na]: 241.0406; Found: 241.0398.




1,3,7-trimethyl-8-(2-oxopyrrolidin-1-yl)-1*H*-purine-2,6(3*H*,7*H*)-dione (6a). Yield: 42%. R_f = 0.20 (100% ethyl acetate); ¹H NMR (300 MHz, CDCl₃) δ 3.97 (t, *J* = 7.0 Hz, 2H), 3.86 (s, 3H), 3.52 (s, 3H), 3.40 (s, 3H), 2.61 (t, *J* = 8.1 Hz, 2H), 2.29 (tt, *J* = 8.1, 7.0 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 174.8, 155.1, 151.6, 146.7, 144.3, 106.5, 49.0, 33.2, 31.0, 29.7, 27.9, 19.1; IR (neat): 1701, 1661, 1512, 1452, 1216 cm⁻¹. HRMS-ESI (*m/z*) calcd. for C₁₂H₁₆N₅O₃ [M+1]: 278.1248. Found: 278.1253.




Ethyl 4-(4-nitrophenyl)-2-(2-oxopyrrolidin-1-yl)-1,3-oxazole-5-carboxylate (7a). Yield: 84%. R_f = 0.20 (100% ethyl acetate); ¹H NMR (500 MHz, CDCl₃) δ 8.31 (d, *J* = 9.0 Hz, 2H), 8.26 (d, *J* = 9.0 Hz, 2H), 4.43 (q, *J* = 7.1 Hz, 2H), 4.10 (t, *J* = 7.2 Hz, 2H), 2.65 (t, *J* = 8.1 Hz, 2H), 2.25 (tt, *J* = 8.1, 7.2 Hz, 2H), 1.40 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 172.7, 161.6, 152.5, 149.0, 147.8, 132.4, 128.7, 128.5, 123.6, 61.9, 47.5, 31.9, 18.3, 14.2; IR (neat): 2984, 1737, 1585, 1344, 1188, 1082, 856, 728 cm⁻¹. HRMS-ESI (*m/z*) calcd. for C₁₆H₁₅N₃O₆Na [M+Na]: 268.0853; Found: 368.0858.




2-(trifluoromethyl)-N-(1,3,7-trimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1*H*-purin-8-yl)benzamide (6i). Yield: 63%. R_f = 0.20 (100% ethyl acetate); ¹H NMR (500 MHz, CDCl₃) δ 8.43 (brs, 1H), 7.85-7.80 (m, 1H), 7.77-7.65 (m, 3H), 3.97 (s, 3H), 3.43 (s, 3H), 3.40 (s, 3H); ¹³C NMR (125 MHz, DMSO-d6) δ 167.5, 155.1, 151.7, 147.0, 144.1, 135.0, 133.2, 131.4, 129.5, 127.2 (q, *J* = 4.5 Hz), 126.9 (q, *J* = 31.0 Hz), 124.4 (q, *J* = 273.5 Hz), 106.3, 32.5, 30.1, 28.2; IR (neat): 3196, 2925, 1709, 1651, 1505, 1315, 1172, 1131 1036, 736 cm⁻¹. HRMS-ESI (*m/z*) calcd. for C₁₆H₁₄F₃N₅O₃Na [M+Na]: 404.0941; Found: 404.0947.




N-(1,3-benzoxazol-2-yl)-2-(trifluoromethyl)benzamide (8i). Yield: 76%. R_f = 0.20 (100% ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ 11.81 (brs, 1H), 7.91 – 7.69 (m, 2H), 7.67 – 7.53 (m, 2H), 7.49 (d, J = 7.6 Hz, 1H), 7.26 (td, J = 7.6, 1.2 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 6.75 (brs, 1H). ^{13}C NMR (125 MHz, DMSO) δ 166.4, 155.9, 148.4, 140.9, 135.6, 133.6, 131.8, 129.7, 127.5 (q, J = 5.0 Hz), 127.0 (q, J = 31.5 Hz), 125.8, 125.0, 124.7 (q, J = 271.5 Hz), 119.2, 111.2; IR (neat): 2927, 1628, 1578, 1552, 1314, 1132, 1109, 743 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{15}\text{H}_9\text{F}_3\text{N}_2\text{O}_2\text{Na}$ [M+Na]: 329.0508; Found: 329.0527.




N-[2-(1*H*-benzimidazol-1-yl)ethyl]-4-methylbenzenesulfonamide (9). Yield: 59%. R_f = 0.20 (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 7.82 (s, 1H), 7.76 (s, 1H), 7.73 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 8.2 Hz, 2H), 7.19 (d, J = 8.1 Hz, 1H), 7.15 (t, J = 7.6 Hz, 1H), 6.99 (t, J = 7.6 Hz, 1H), 4.30 (t, J = 4.9 Hz, 2H), 3.39 (t, J = 4.9 Hz, 2H), 2.39 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 143.3, 143.2, 142.5, 137.3, 132.8, 129.7, 126.8, 123.0, 122.3, 119.3, 109.3, 45.7, 42.1, 21.5. IR (neat): 3093, 1498, 1327, 1157, 1093, 744 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{16}\text{H}_{17}\text{N}_3\text{O}_2\text{SNa}$ [M+Na]: 338.0934; Found: 338.0930.




N-[3-(1*H*-benzimidazol-1-yl)propyl]-4-methylbenzenesulfonamide (10). Yield: 59%. R_f = 0.20 (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 7.90 (s, 1H), 7.84 – 7.73 (m, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.38 – 7.32 (m, 1H), 7.30 – 7.17 (m, 4H), 6.84 (t, J = 5.9 Hz, 1H), 4.31 (t, J = 6.6 Hz, 2H), 2.88 (q, J = 5.9 Hz, 2H), 2.38 (s, 3H), 2.10 – 2.04 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 143.4, 143.4, 136.5, 133.3, 129.7, 126.9, 123.0, 122.3, 120.1, 109.7, 41.7, 39.6, 29.2, 21.4. IR (neat): 3056, 1501, 1318, 1153, 748, 551 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}_2\text{SNa}$ [M+Na]: 352.1090; Found: 352.1097.




1-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[1,2-*a*]benzimidazole (11). Yield: 86%. R_f = 0.50 (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 7.99 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 8.2 Hz, 2H), 7.18 (t, J = 7.5 Hz, 1H), 7.14 – 7.06 (m, 2H), 4.36 (t, J = 7.6 Hz, 2H), 4.10 (t, J = 7.6 Hz, 2H), 2.37 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 152.9, 147.5, 145.2, 133.2, 131.4, 129.9, 128.0, 122.1, 121.7, 119.6, 108.4, 51.6, 39.8, 21.6. IR (neat): 1544, 1434, 1277, 1170, 1089, 572 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}_2\text{SNa}$ [M+Na]: 336.0777; Found: 336.0775.




1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydropyrimido[1,2-*a*]benzimidazole (12). Yield: 90%. R_f = 0.50 (100% ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ 8.08 (d, J = 8.3 Hz, 2H), 7.67 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.3 Hz, 2H), 7.22 – 7.05 (m, 3H), 4.04 (t, J = 5.5 Hz, 2H), 3.98 (t, J = 6.2 Hz, 2H), 2.37 (s, 3H), 2.30 (tt, J = 6.2, 5.5 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 144.9, 144.5, 141.1, 135.3, 133.1, 129.4, 128.5, 122.2, 121.1, 118.9, 107.8, 44.7, 40.7, 21.9, 21.6. IR (neat): 1525, 1436, 1286, 1150, 671 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{17}\text{H}_{18}\text{N}_3\text{O}_2\text{S}$ [M+1]: 328.1114; Found: 328.1120.




1-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]pyrrolidin-2-one (13a). Yield: 22%. R_f = 0.40 (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 3.84 (t, J = 7.0 Hz, 2H), 2.62 (t, J = 8.0 Hz, 2H), 2.35 (tt, J = 8.0, 7.0 Hz, 2H). ^{19}F NMR (282 MHz, CDCl_3) δ -56.24 (t, J = 21.8 Hz, 3F), -139.62 – -140.63 (m, 2F), -141.26 – -142.13 (m, 2F). ^{13}C NMR (125 MHz, CDCl_3) δ 174.2, 146.6, 145.7 – 144.4 (m), 143.6 – 142.4, 121.8, 94.7, 48.9 (t, J = 2.1 Hz), 30.0, 19.6. IR (neat): 1728, 1503, 1346, 1272, 1145, 987, 715 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{11}\text{H}_7\text{NF}_7\text{NO}$ [M+1]: 302.0410; Found: 302.0423.





1-(2,3,5,6-tetrafluorophenyl)pyrrolidin-2-one (14a). Yield: 33%. $R_f = 0.50$ (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 7.06 (tt, $J = 9.7, 7.0$ Hz, 1H), 3.80 (t, $J = 7.0$ Hz, 2H), 2.59 (t, $J = 8.1$ Hz, 2H), 2.31 (tt, $J = 8.1, 7.0$ Hz, 2H); ^{19}F NMR (282 MHz, CDCl_3) δ -138.42 – -138.67 (m, 2F), -144.14 – -144.85 (m, 2F). ^{13}C NMR (125 MHz, CDCl_3) δ 174.5, 146.07 (dddd, $J = 248.7, 13.0, 11.5, 4.1$ Hz), 144.54 – 141.90 (ddt, $J = 248.7, 14.4, 3.6$ Hz), 118.45 (tt, $J = 14.4, 2.7$ Hz), 105.03 (t, $J = 22.8$ Hz), 49.08 (t, $J = 1.8$ Hz), 30.1, 19.4. IR (neat): 3046, 1698, 1514, 1495, 1251, 945 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{11}\text{H}_7\text{NF}_7\text{NO}$ [M+1]: 302.0410; Found: 302.0423.




1,1'-(2,3,5,6-tetrafluorobenzene-1,4-diyl)dipyrrolidin-2-one (14aa). Yield: 71%. $R_f = 0.20$ (100% ethyl acetate); ^1H NMR (500 MHz, CDCl_3) δ 3.78 (t, $J = 7.0$ Hz, 4H), 2.59 (t, $J = 8.1$ Hz, 4H), 2.31 (tt, $J = 8.1, 7.0$ Hz, 4H); ^{19}F NMR (282 MHz, CDCl_3) δ -144.42 (s, 4F); ^{13}C NMR (75 MHz, CDCl_3) δ 174.7, 145.6 – 141.9 (m), 117.4 – 117.0 (m), 49.1, 30.0, 19.4. IR (neat): 1705, 1502, 1395, 1251, 977 cm^{-1} , HRMS–ESI (m/z) calcd. for $\text{C}_{14}\text{H}_{12}\text{F}_4\text{N}_2\text{O}_2\text{Na}$ [M+Na]: 339.0727; Found: 39.0734.




3a





3a







3b





3b








3c





3c









3e





3e







3f





3f









3g




3g














3j





3j










31





31









3n





3n








3o





3o









5a





5a







6a





6a







7a





7a









6i





6i











9





9









11





11







12





12







13a





13a







13a





14a







14a





14a







14aa



14aa





14aa

